Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Genome-wide association studies have begun to elucidate the genetic architecture of type 2 diabetes. We examined whether single nucleotide polymorphisms (SNPs) identified through targeted complementary approaches affect diabetes incidence in the at-risk population of the Diabetes Prevention Program (DPP) and whether they influence a response to preventive interventions. RESEARCH DESIGN AND METHODS: We selected SNPs identified by prior genome-wide association studies for type 2 diabetes and related traits, or capturing common variation in 40 candidate genes previously associated with type 2 diabetes, implicated in monogenic diabetes, encoding type 2 diabetes drug targets or drug-metabolizing/transporting enzymes, or involved in relevant physiological processes. We analyzed 1,590 SNPs for association with incident diabetes and their interaction with response to metformin or lifestyle interventions in 2,994 DPP participants. We controlled for multiple hypothesis testing by assessing false discovery rates. RESULTS: We replicated the association of variants in the metformin transporter gene SLC47A1 with metformin response and detected nominal interactions in the AMP kinase (AMPK) gene STK11, the AMPK subunit genes PRKAA1 and PRKAA2, and a missense SNP in SLC22A1, which encodes another metformin transporter. The most significant association with diabetes incidence occurred in the AMPK subunit gene PRKAG2 (hazard ratio 1.24, 95% CI 1.09–1.40, P = 7 × 10−4). Overall, there were nominal associations with diabetes incidence at 85 SNPs and nominal interactions with the metformin and lifestyle interventions at 91 and 69 mostly nonoverlapping SNPs, respectively. The lowest P values were consistent with experiment-wide 33% false discovery rates. CONCLUSIONS: We have identified potential genetic determinants of metformin response. These results merit confirmation in independent samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Inference of Population Structure Using Multilocus Genotype Data
Pritchard, J. K., Stephens, M., & Donnelly, P. (2000) · Genetics · doi:10.1093/genetics/155.2.945 · Cited by 33,908
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843
Self-citationThe Wellcome Trust Case Control Consortium, U.K.
Mossman, K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-42a · Cited by 2,684
Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · cited 9×
“Category n Candidate genes (n SNPs) 1,256 Comprehensive coverage 1,241 Monogenic diabetes 317 ABCC8 (84), GCK (37), HNF1A (20), HNF1B (74), HNF4A (66), KCNJ11 (9), NEUROD1 (14), PDX1 (13) Monogenic obesity 21 MC4R (21) Previously associated with type 2 diabetes 60 CAPN10 (33), PTPN1 (27) Drug targets 190 PPARG (59), P…”
BackgroundInfluentialWellcome Trust Case Control Consortium, Zeggini, E., Scott, L. J., Saxena, R., Voight, B. F., Marchini, J. L., Hu, T., de Bakker, P. I., Abecasis, G. R., Almgren, P., et al. (2008) · Nature Genetics · doi:10.1038/ng.120 · Cited by 1,864
Self-citationthe GIANT Consortium (2009) · Nature Genetics · doi:10.1038/ng.287 · Cited by 1,720
Efficiency and power in genetic association studies
de Bakker, P. I. W., Yelensky, R., Pe'er, I., Gabriel, S. B., Daly, M. J., & Altshuler, D. (2005) · Nature Genetics · doi:10.1038/ng1669 · Cited by 1,688
Self-citation
Research works printed but not linked: 1
- Li, 2006, Mach 1.0: Rapid haplotype reconstruction and missing genotype inference, Am J Hum Genet S, 79, 2290
Cited by
Items 201–274 of 274
The interplay of lifestyle and genetic susceptibility in Type 2 diabetes risk
Franks, P. W., & Shungin, D. (2011) · Diabetes Management · doi:10.2217/dmt.11.3 · Cited by 4
Self-citationFRADKIN, J. E., Wallace, J. A., & Rodgers, G. P. (2013) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2012.12.017 · Cited by 3
Efectividad de la metformina en pacientes con diabetes tipo II según variantes en el gen SLC22A1
Yang, P., Nicolás, J., Galván, C. A., Velez, P. S., Ronco, L. D., Díaz, G. T., Beltramo, D. M., & Soria, N. W. (2014) · Americanae (AECID Library) · Cited by 3
Gu, R., & Syed, N. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.417 · Cited by 4
Ludovico, O., Farina, M. G., Copetti, M., Palena, A. P., Proto, V., Marotta, V., Strippoli, G. F., Frittitta, L., Trischitta, V., & Prudente, S. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.05.008 · Cited by 3
Florez, J. C., Udler, M. S., & Hanson, R. L. (2021) · Europe PMC (PubMed Central) · Cited by 6
Self-citationThe ongoing epidemic of diabetes mellitus in India: genetics or lifestyle?
Thomas, E. T. A., Shaji, B., & Gracious, N. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0630-5 · Cited by 3
Glatard, A., Guidi, M., Dobrinas, M., Cornuz, J., Csajka, C., & Eap, C. B. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02662-9 · Cited by 4
The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management
Aquilante, C. L., & Lam, Y. W. F. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391918-2.00007-x · Cited by 2
Sarah, E. H., Omri, N. E., Ibrahimi, A., & Jaoudi, R. E. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100787 · Cited by 2
Naz, F., Qadir, R., Baammi, S., Ali, A., & Rehman, M. U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15336-5.00012-9 · Cited by 2
Methnani, J., Ach, T., Hraïech, A. E., Latiri, I., Bouslama, A., Zaouali, M., Omezzine, A., & Bouhlel, E. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117112 · Cited by 2
Pharmacogenomics of Oral Antidiabetic Drugs
Manolopoulos, V. G., & Ragia, G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00030-x · Cited by 2
Population Genetics and Pharmacogenetics
Ong, K. K., & Elks, C. E. (2010) · Yearbook of pediatric endocrinology · doi:10.1159/000320661 · Cited by 2
Progress, pitfalls, and prospects
Franks, P. W., Pearson, E. R., & Florez, J. C. (2013) · Cited by 2
Self-citationUdler, M. S., & Florez, J. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800685-6.00014-x · Cited by 2
Self-citationGuo, M., Ren, Q., Yang, F., Han, T., Du, W., Zhao, F., Li, W., Li, J., Feng, Y., Zhang, Y., et al. (2021) · Diabetic Medicine · doi:10.1111/dme.14613 · Cited by 2
Governmental and Academic Efforts to Advance the Field of Pharmacogenomics
Cavallari, L. H., Klein, T. E., & Huang, S. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391918-2.00003-2 · Cited by 2
Glycaemic responses to metformin monotherapy by SNP clusters in patients with type 2 diabetes
Sheu, W. H., Lee, C., Wang, Y., Liao, C.-S., Hsiao, T., Ken, S., Hatzikotoulas, K., Morris, A. P., Initiative, T. T. 2. D. G. G., Chen, Y. I., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70023 · Cited by 1
Interventional Trials to Prevent Diabetes: Diabetes Prevention Program
Aroda, V. R., & Ratner, R. E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3314-9_9 · Cited by 2
Florez, J. C. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00082-3 · Cited by 1
Self-citationCommon Sources of Bias in Gene–Lifestyle Interaction Studies of Cardiometabolic Disease
Kilpeläinen, T. O. (2013) · Current Nutrition Reports · doi:10.1007/s13668-013-0056-0 · Cited by 2
Franks, P. W., Christophi, C. A., Jablonski, K. A., Delahanty, L. M., Horton, E. S., Knowler, W. C., & Florez, J. C. (2013) · Diabetologia · doi:10.1007/s00125-013-2911-3 · Cited by 1
Self-citationRetractedGenetics of Drug Response in Diabetes
Pearson, E. R., & Florez, J. C. (2014) · Frontiers in diabetes · doi:10.1159/000362475 · Cited by 1
Self-citationPhase 1–Phase 3 Clinical Studies, Procedures, Responsibilities, and Documentation
Yanni, S. B. (2015) · Wiley eBooks · doi:10.1002/9781118838440.ch10 · Cited by 1
Arshad, S., Khan, A., Melwani, V., Sethia, S., Priya, A., & Melwani, S. (2018) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20182619 · Cited by 1
Virginia, D. M., Wahyuningsih, M. S. H., & Nugrahaningsih, D. A. A. (2021) · Asian Biomedicine · doi:10.2478/abm-2021-0021 · Cited by 1
Role of Genetic and Environmental Factors in Determining the Response to Metformin
Николаевна, К. А., & Бабушкина, Н. П. (2021) · Diabetes Mellitus · doi:10.14341/dm12744 · Cited by 1
Perwitasari, D. A., Faridah, I. N., Dania, H., Irham, L. M., Salsabila, F. V., & Maliza, R. (2020) · Selamat Datang di Repository UAD (Universitas Ahmad Dahlan) · doi:10.31838/srp.2020.9.92 · Cited by 1
Virginia, D. M., Wahyuningsih, M. S. H., & Nugrahaningsih, D. A. A. (2020) · doi:10.21203/rs.3.rs-107043/v1 · Cited by 2
Mechanisms under Metformin and Rapamycin as Anti-aging DrugsPreprint
Feng, Q., Chen, B., Wang, C., Nie, C., & Li, T. (2020) · Authorea · doi:10.22541/au.159372989.91282630 · Cited by 1
Review: Updates of precision medicine in type 2 diabetes — R1/PR8
Xia, M., & Li, X. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr8 · Cited by 1
Translating Advances in Our Understanding of the Genetics of Diabetes into the Clinic
Gardner, D. S.-L., Owen, K. R., & Gloyn, A. L. (2014) · Frontiers in diabetes · doi:10.1159/000362476
Genome-wide association studies of Type 2 diabetes: are these ready to make an impact in the clinic?
Thanabalasingham, G., Gloyn, A. L., & Owen, K. R. (2011) · Diabetes Management · doi:10.2217/dmt.11.30
Nutrigenetics of Type 2 Diabetes
Qi, L., & Franks, P. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-01574-3_26
Self-citationAndo, H. (2016) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.47.173
Clinical Implications of Pharmacogenetic Data
Chiara, G. (2012)
Фармакогенетичні аспекти дії метформіну у хворих на цукровий діабет 2-го типу
Пасечко, Н. В., Oleshchuk, O., & Лой, Г. Я. (2017) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.8.80.2016.89542
Hızel, C., Tremblay, J., Bartlett, G., & Hamet, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809411-2.00001-5
Pharmacogenomics of Type 2 Diabetes Mellitus
Surendiran, A., Saranya, V., & Anusha, N. (2017) · SBV Journal of Basic Clinical and Applied Health Science · doi:10.5005/jp-journals-10082-01102
Metformin: Pharmacogenetics and metabolic effects
Out (2018) · Research Publications (Maastricht University) · doi:10.26481/dis.20180709mo
Guénard, F., Marceau, S., Simard, S., Kral, J. G., Vohl, M., & Marceau, P. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/435461
Governmental and Academic Efforts to Advance the Field of Pharmacogenomics
Momary, K. M., & Drozda, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00002-4 · Cited by 2
Pharmacogenomics of Type 2 Diabetes Mellitus; A Step Toward Personalized Medicine
Zia, A., Bhatti, A., John, P., & Kiani, A. K. (2021) · NUST Journal of Natural Sciences · doi:10.53992/njns.v3i1.16
Munansangu, B. S. M. (2018) · Boloka Institutional Repository (North-west University)
Zhou, K., & Pearson, E. R. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.30
Hivert, M., & Knowler, W. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-01574-3_25
Self-citationPopulation Genetics and Pharmacogenetics
Ong, K. K. (2011) · Yearbook of pediatric endocrinology · doi:10.1159/000330706
Association of PPARG and PPARGC1 polymorphism with effectiveness of exercise-induced fat mass loss
Mazur, I. I., Drozdovska, S., Валеріївна, А. О., Vinnichuk, Y. D., Polishchuk, A., Andreev, I. O., Досенко, В. Є., Pickering, C., & Ahmetov, I. I. (2020) · Faktori eksperimental noi evolucii organizmiv · doi:10.7124/feeo.v27.1326
Review: Updates of precision medicine in type 2 diabetes — R1/PR7
Xia, M., & Li, X. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr7
Author comment: Updates of precision medicine in type 2 diabetes — R1/PR6
Li, X. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr6
Recommendation: Updates of precision medicine in type 2 diabetes — R0/PR4
Xia, M., & Li, X. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr4
Decision: Updates of precision medicine in type 2 diabetes — R1/PR10
Xia, M., & Li, X. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr10
Recommendation: Updates of precision medicine in type 2 diabetes — R1/PR9
Xia, M., & Li, X. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr9
Decision: Updates of precision medicine in type 2 diabetes — R0/PR5
Xia, M., & Li, X. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr5
Review: Updates of precision medicine in type 2 diabetes — R0/PR2
Xia, M., & Li, X. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr2
Author comment: Updates of precision medicine in type 2 diabetes — R0/PR1
Li, X. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr1
Review: Updates of precision medicine in type 2 diabetes — R0/PR3
Xia, M., & Li, X. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.12.pr3
Raza, M. K., Aamir, A.-U.-H., Mansour, L. A., Khan, Z., Shahwar, D.-E., Ali, A., & Imran, M. (2024) · Research Square · doi:10.21203/rs.3.rs-3947421/v1
Li, Z., Ye, C.-Y., Zhao, T., & Yang, L. (2020) · Figshare · doi:10.6084/m9.figshare.12586055
Pharmacogenomics: The roles of genetic factors on treatment response and outcomes in diabetes
Wang, K., Chow, E., & Tomlinson, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95686-4.00026-5
Personalized epigenetic management of diabetes
Sapehia, D., Bhardwaj, N., Goyal, H., Mahajan, A., Singh, P., & Kaur, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23802-4.00017-x · Cited by 1
Trends and challenges in managing diabetes mellitus-personalized medicine
Alaoufi, S. M., Alanazi, M. M., ALKhabbaz, G. G., Alharbi, Y. F., Almutairi, D. B., Almutairi, K. A., & Alamri, S. A. (2017) · International Journal of Health Sciences · doi:10.53730/ijhs.v1ns1.15130
Drug Transporters Polymorphism Among Indonesian Population: A Review
Adhayanti, I., & Gafur, A. (2025) · Futurity Medicine. · doi:10.57125/fem.2025.06.30.04
The Genetics and Pharmacogenetics of Diabetes in Africa: Towards Personal Diabetes Care
Boukhalfa, W., Kéfi, R., & Chaouch, M. (2025) · Springer eBooks · doi:10.1007/978-981-96-8959-0_4
The Genetics of Metabolic Syndrome in Africa: Towards Precision Medicine
Jmel, H., Kéfi, R., & Kassim, S. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-8959-0_3
Pharmacogenetic factors that affect drug metabolism and efficacy in type 2 diabetes mellitus
Li, X., & Liu, Z. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29289-7.00022-9
Functional genomics approaches to dissect causal DNA variations in obesity and type 2 diabetes
Huang, M. (2023) · Lund University Publications (Lund University)
CANTOR, S. L., Zeng, Y., Davis, F., Glaros, S. B., Macheret, N. A., KACKER, I. N., Malandrino, N., Mabundo, L., Arisa, O. T., Adeyemo, A., et al. (2026) · medRxiv · doi:10.64898/2026.05.27.26354152
Raghavan, S., & Lange, L. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00015-9
Hossain, I., Haidar, M., Ratul, M. A., Ferdous, J., Shabnaz, S., Nokib, A. F., & Zohora, F. T. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70343
Postprandial glucose management of people with insulin-treated diabetes
McGill, J. B., Hirsch, I. B., Levy, C. J., Cengiz, E., Aleppo, G., & Carlson, A. L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1947837
Raj, K. P., & Sabarees, G. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02875-x
Breitenstein, M. K. (2015) · University of Minnesota Digital Conservancy (University of Minnesota)
Metadata
- Authors
- Jablonski, K. A., McAteer, J. B., de Bakker, P. I. W., Franks, P. W., Pollin, T. I., Hanson, R. L., Saxena, R., Fowler, S., Shuldiner, A. R., Knowler, W. C., Altshuler, D., Florez, J. C., & for the Diabetes Prevention Program Research Group
- Affiliations
- George Washington University (US)
- Broad Institute (US)
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts;
- Lund University (SE)
- University of Maryland, Baltimore (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts;
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-08-03
- Volume
- 59
- Issue
- 10
- Pages
- 2672-2681
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3279522
- OpenAlex
- W2137393786
- Cited by
- 271
- References
- 35
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 10 · 2023: 17 · 2022: 12 · 2021: 13 · 2020: 16 · 2019: 18 · 2018: 19 · 2017: 21 · 2016: 24 · 2015: 18 · 2014: 25 · 2013: 25 · 2012: 23
- FWCI
- 11.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072041, U01DK048489)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, single nucleotide polymorphisms, metformin response, lifestyle intervention, Diabetes Prevention Program, SLC47A1, AMPK, PRKAG2, STK11, PRKAA1, PRKAA2, SLC22A1, genetic susceptibility, gene-environment interaction, diabetes prevention
- MeSH terms
- Adult, Diabetes Mellitus, Diabetes Mellitus, Type 2, Ethnicity, Female, Genotype, Hemeproteins, Humans, Life Style, Male, Metformin, Middle Aged, Genetic Variation, Body Mass Index, Incidence, Polymorphism, Single Nucleotide, Organic Cation Transport Proteins, Racial Groups, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.